A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (ASCENT)
This study has been completed.
Information provided by (Responsible Party):
First received: April 27, 2012
Last updated: August 10, 2017
Last verified: July 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||September 30, 2016|
|Primary Completion Date:||September 30, 2016 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer. 2013 Mar 15;13:120. doi: 10.1186/1471-2407-13-120.